Articles and Insights About Wearables for Clinical Trials

Vivosense is pleased to announce that Rob Wilson has joined the company as VP of Marketing Strategy. He brings more than 30 years of expertise in strategic planning, finance, and business development for a wide range of companies in digital health, biotechnology, medical technology, and healthcare service industries.

Proceeds to accelerate the collection and use of wearable sensor data in clinical trials along with the development of novel digital biomarkers.

Funding round co-led by the Perceptive Xontogeny Venture (PXV) Fund and Switzerland-based Debiopharm Innovation Fund.

NEWPORT BEACH, Calif. – March 30, 2022-- VivoSense, Inc., (“VivoSense”) an agile end-to-end scientific solutions company developing novel digital endpoints from wearable sensor data, today announced the close of a $25 Million Series A financing round. The financing will accelerate the development of novel digital biomarkers and improve digital clinical outcome assessments (COAs). VivoSense will also use this financing to expand and refine its informatics platform for data analysis from wearable and connected technologies to deliver validated digital COAs for life science research.

The best way to understand how VivoSense^®️ software can help you visualize physiological data from your clinical trial is to see it in action. The first video below will take you through the graphical user interface, importing and opening a physiological data session, and exploring the data with the Data Explorer panel and the synchronized chart panel.

The second video will discuss some advanced tools, such as the channel chart and plot properties, create some save layouts for use with all data sessions, create annotation markings to identify events in the data, and export the data to ASCII.

In this video, Dudley Tabakin, VivoSense CEO, shares an example of how rare disease researchers can use wearable sensors to develop digital clinical measures to improve patient outcomes. He discusses our approach to developing outcome measures from ECG Derived Respiration (EDR) to discover novel respiratory endpoints for Rett Syndrome, working with Rett Syndrome Research Trust.

Respiratory abnormalities characterize a variety of disorders. In addition to physical disorders, ventilation is profoundly affected by mental and psychophysiological states, including stress, anxiety, and panic disorder. Let’s take a look at respiratory-related health issues and the promising wearable technology available to assess respiratory outcome measures in real-world settings.

Digital health technologies have the potential to transform clinical drug development. They can collect continuous, high-resolution data in patients’ real-world environments for extended periods of time, providing researchers with an unprecedented level of insight into patients’ physiological and behavioral states. These types of data may more accurately describe a patient’s experience and enable previously unattainable scientific undertakings.

To drive scientific progress and increase digital medicine acceptance, the Digital Medicine Society (DiMe) has created The Playbook: Digital Clinical Measures, “ the essential industry guide for successfully developing & deploying digital clinical measures across clinical research, clinical care, and public health.”

We are excited to be included in the Tour of Duty, a team of experienced tech, pharma, clinical leaders, regulators, and patient advocates driving the adoption of a shared foundation for the digital health field.

VivoSense, Inc. is proud to announce that we have been awarded an NIH/NCI Phase 1 contract to develop software enabling data integration from wearable sensors for cancer patients. The contract will result in the development of the VivoSense Cancer Health Informatics Platform as the leading wearable sensor agnostic cloud platform for cancer research and clinical care.

As the leading provider of visualization and analysis software for data from wearable sensors, we are committed to continually improving VivoSense and expanding its capabilities for our academic research partners. Here are some of the highlights of our recent release of VivoSense^® 3.5.

The 3rd Annual Digital Biomarkers in Clinical Trials Summit hosted by Roche was the virtual place to be in June, bringing together 250+ global thought leaders and experts. They shared insights on developing and improving the way pharma clinical trials utilize mobile-enabled, wearables, and IoT capabilities to augment existing biomarker strategies, improve patient experience, and collect better data.